#Netherlands #Amsterdam #ADC technology #Synaffix #Elevation Oncology

Elevation Oncology Partners with Synaffix to Innovate ADC Development

Synopsis
Elevation Oncology has entered into a strategic licensing agreement with Synaffix, a leading biotechnology firm specializing in antibody-drug conjugate (ADC) technologies. This collaboration aims to expedite the development of new therapies that address critical cancer treatment gaps, specifically targeting solid tumors that express the HER3 protein, through the innovative application of Synaffix's proprietary technologies.

The Agreement and Its Implications

On December 12, 2024, Synaffix B.V., a Lonza company, announced that it has granted Elevation Oncology the rights to utilize its cutting-edge ADC technology. The agreement covers the incorporation of Synaffix’s advanced GlycoConnect®, HydraSpace®, and toxSYN® technology platforms into Elevation's pipeline, particularly for a novel HER3-targeting ADC candidate, EO-1022. This partnership is expected to provide Elevation with the means to develop a differentiated ADC, potentially possessing best-in-class properties and improved therapeutic indices.

Financial Aspects of the Deal

The terms of this licensing deal are noteworthy; Synaffix stands to gain up to USD 368 million through initial payments and various milestone targets including clinical, regulatory, and commercial achievements. Additionally, Synaffix will receive tiered royalties based on net sales from the commercially successful ADC products derived from this collaboration.

Expert Insights

Peter van de Sande, Synaffix’s Head, expressed enthusiasm for the collaboration, viewing it as a vital step towards advancing ADC solutions. He emphasized that with the robust capabilities of their technology platform and established supply chain, Elevation is strategically positioned to speed up the development of innovative HER3-targeting therapies.

David Dornan, Chief Scientific Officer at Elevation Oncology, highlighted the unique potential of the HER3 ADC candidate in aiding patients with cancers characterized by HER3 expression. He remarked on how the partnership will enable the development of a product designed to optimize safety and effectiveness—a crucial advancement for solid tumor therapies.

Overview of Synaffix's ADC Technologies

Synaffix has made significant strides in the ADC development landscape with its integrated technology platforms. The GlycoConnect® technology allows for site-specific drug attachment via the antibody's native glycan, enhancing stability and therapeutic efficacy. Furthermore, HydraSpace® facilitates a more effective therapeutic index, especially with hydrophobic agents, while the toxSYN® linker-payload technology encompasses various mechanisms of action, providing a versatile toolkit for ADC development.

These technologies streamline the ADC development process, enabling biopharma companies to transition from concept to clinic rapidly. Synaffix has established a proven track record of collaborations with numerous organizations, enhancing its credibility as a partner.

Elevation Oncology's Mission and Pipeline

Elevation Oncology is dedicated to creating targeted therapies that fulfill unmet medical needs in oncology. The company's innovative approach focuses on precision medicine, utilizing their expertise in ADC technology. With candidates like EO-3021 and EO-1022 in their pipeline, Elevation is intensifying its commitment to revolutionizing cancer treatment through cutting-edge science.

Conclusion

The partnership between Elevation Oncology and Synaffix marks a significant milestone in the fields of oncology and ADC development. As both companies strive to improve patient outcomes through innovative treatments, this collaboration could pave the way for novel therapies that effectively target difficult-to-treat solid tumors. As development progresses, the biopharma community and patients alike will be keenly watching the advancements emerging from this strategic alliance.